Biblio Discovery — Demo Discovery Service

23 hasil untuk "Jonathan Kay"

Menampilkan 1–20 · 0,57 detik · RSS

  1. Artikel Jurnal

    Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis

    Jeffrey R. Curtis; Fenglong Xie; Jonathan Kay dkk.

    Arthritis Research & Therapy, Vol. 21 No. 1 · 2019 · Inggris · DOAJ Scopus

    Abstract Introduction Biosimilar infliximab has the potential for appreciable cost savings compared to its reference biologic, but dose escalation is common and increases costs. We compared frequency of dose escalation and associated Medicare-approved amount so as to determine the break-even point…

  2. Artikel Jurnal

    Modeling the Effects of Formulary Exclusions: How Many Patients Could Be Affected by a Specific Exclusion?

    Anne M. Sydor; Emily Bergin; Jonathan Kay dkk.

    Journal of Health Economics and Outcomes Research, Vol. 11 No. 1 · 2024 · Inggris · DOAJ Scopus

    # Background Medication formularies, initially designed to promote the use of cost-effective generic drugs, are now designed to maximize financial benefits for the pharmacy benefit management companies that negotiate purchase prices. In the second-largest pharmacy benefit management formulary that…

  3. Artikel Jurnal

    Biosimilars in rheumatology: what the clinician should know

    Jonathan Kay; Gilberto Castañeda-Hernández; Rodrigo González-Ramírez dkk.

    RMD Open, Vol. 1 No. 1 · 2015 · Inggris · DOAJ Scopus

    Biosimilars are now a reality in rheumatology. Although analytical and non-clinical procedures to establish similarity have evolved significantly, clinical trials demonstrating equivalent efficacy and safety are absolutely required for all biosimilars. The design of such trials, including…

  4. Artikel Jurnal

    Use of multibiomarker disease activity scores in biosimilarity studies for the treatment of patients with rheumatoid arthritis

    Jonathan Kay; Muhammad Rehman; Noriko Iikuni dkk.

    RMD Open, Vol. 8 No. 2 · 2022 · Inggris · DOAJ Scopus

    Objectives This exploratory analysis investigated the potential use of the multibiomarker disease activity (MBDA) score to support biosimilarity assessments using data from two randomised controlled trials (RCTs) of biosimilar infliximab (IFX-qbtx) and biosimilar adalimumab (ADL-afzb) versus…

  5. Artikel Jurnal

    Comanagement with rheumatology and prescription biologics filled during pregnancy in women with rheumatic diseases: a retrospective analysis of US administrative claims data

    Jonathan Kay; Kate L Lapane; Divya Shridharmurthy dkk.

    BMJ Open, Vol. 12 No. 12 · 2022 · Inggris · DOAJ Scopus

    Objectives To evaluate comanagement with rheumatology and biological prescriptions filled during pregnancy among women with axial spondyloarthritis (axSpA), rheumatoid arthritis (RA) or psoriatic arthritis (PsA) and to examine factors associated with receiving comanagement with rheumatology during…

  6. Artikel Jurnal Teks lengkap

    Development and test-retest reliability of a screening tool for axial spondyloarthritis.

    Divya Shridharmurthy; Kate L Lapane; Sara Khan dkk.

    PLoS ONE, Vol. 17 No. 7 · 2022 · Inggris · DOAJ Scopus

    BackgroundPeople with axial Spondyloarthritis (axSpA) suffer from lengthy diagnostic delays of ~7 years. The usage of screening tools to identify axSpA patients in primary care can reduce diagnostic delays by facilitating early referral to rheumatologic care. The purpose of this study was to…

    Juga tersedia di: PLOS

  7. Artikel Jurnal

    Treatment Persistence and Switching Patterns of Adalimumab Biosimilar ABP 501 in European Patients with Rheumatologic Diseases

    Ran Jin; Silvia Kruppert; Florian Scholz dkk.

    Rheumatology and Therapy, Vol. 11 No. 3 · 2024 · Inggris · DOAJ Scopus

    Abstract Introduction ABP 501 was an adalimumab (ADA) biosimilar approved for treating immune-mediated inflammatory diseases (IMIDs) including rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). In this retrospective study, we aimed to examine the treatment…

  8. Artikel Jurnal

    Primary care physician perspectives on barriers to diagnosing axial Spondyloarthritis: a qualitative study

    Kate L. Lapane; Sara Khan; Divya Shridharmurthy dkk.

    BMC Family Practice, Vol. 21 No. 1 · 2020 · Inggris · DOAJ

    Abstract Background The average delay in diagnosis for patients with axial spondyloarthritis (axSpA) is 7 to 10 years. Factors that contribute to this delay are multifactorial and include the lack of diagnostic criteria (although classification criteria exist) for axSpA and the difficulty in…

  9. Artikel Jurnal

    Patient perspectives on health care provider practices leading to an axial spondyloarthritis diagnosis: an exploratory qualitative research study

    Kate L. Lapane; Catherine Dubé; Katarina Ferrucci dkk.

    BMC Family Practice, Vol. 22 No. 1 · 2021 · Inggris · DOAJ

    Abstract Background The average time to a diagnosis for people with axial spondyloarthritis (axSpA) is 7-10 years. Delayed diagnosis may result in increased structural damage, worse physical function, and worse quality of life relative to patients with a timely axSpA diagnosis. Understanding…

  10. Artikel Jurnal Teks lengkap

    Primary care physician perspectives on screening for axial spondyloarthritis: A qualitative study.

    Kate L Lapane; Divya Shridharmurthy; Sara Khan dkk.

    PLoS ONE, Vol. 16 No. 5 · 2021 · Inggris · DOAJ Scopus

    BackgroundMany patients with axial spondylarthritis (axSpA) experience lengthy diagnostic delays upwards of 14 years. (5-14 years). Screening tools for axSpA have been proposed for use in primary care settings, but whether this approach could be implemented into busy primary care settings remains…

    Juga tersedia di: PLOS

  11. Artikel Jurnal

    Fipronil and ivermectin treatment of cattle reduced the survival and ovarian development of field-collected Anopheles albimanus in a pilot trial conducted in northern Belize

    Staci M. Dreyer; Donovan Leiva; Marla Magaña dkk.

    Malaria Journal, Vol. 18 No. 1 · 2019 · Inggris · DOAJ Scopus

    Abstract Background Most malaria vector control programmes rely on indoor residual spraying of insecticides and insecticide-treated bed nets. This is effective against vector species that feed indoors at night and rest inside the house afterwards. In Central America, malaria vectors have different…

  12. Artikel Jurnal

    Transthoracic echocardiography is adequate for intraprocedural guidance of transcatheter aortic valve implantation

    Renuka Jain; Daniel P O’Hair; Tanvir K Bajwa dkk.

    Echo Research and Practice, Vol. 4 No. 4 · 2017 · Inggris · DOAJ Scopus

    Background: While transcatheter aortic valve implantation (TAVI) has traditionally been supported intraprocedurally by transoesophageal echocardiography (TOE), transthoracic echocardiography (TTE) is increasingly being used. We evaluated echocardiographic imaging characteristics and clinical…

  13. Artikel Jurnal

    A new education agenda based on The International Science and Evidence Based Education Assessment

    Nandini Chatterjee Singh; Tal Gilead; Anya Chakraborty dkk.

    npj Science of Learning, Vol. 10 No. 1 · 2025 · Inggris · DOAJ Scopus

    Abstract The International Science and Evidence Based Education Assessment examined whether current education systems develop each person’s full potential (aligned with the UN Declaration of Human Rights) and contribute to Sustainable Development Goal 4. Embracing a multidisciplinary approach…

  14. Buku Teks lengkap

    The Value of Hawaiʻi 3

    Goodyear-Ka‘ōpua, Noelani; Howes, Craig; Osorio, Jonathan Kay Kamakawiwoʻole dkk.

    University of Hawai'i Press · 2020 · Inggris · OAPEN

    “Hulihia” refers to massive upheavals that change the landscape, overturn the normal, reverse the flow, and sweep away the prevailing or assumed. We live in such days. Pandemics. Threats to ʻāina. Political dysfunction, cultural appropriation, and disrespect. But also powerful surges toward…

  15. Artikel Jurnal

    Examining Treatment Decision‐Making Among Patients With Axial Spondyloarthritis: Insights From a Conjoint Analysis Survey

    Woojin Joo; Christopher V. Almario; Mariko Ishimori dkk.

    ACR Open Rheumatology, Vol. 2 No. 7 · 2020 · Inggris · DOAJ Scopus

    Objective The number of therapies for axial spondyloarthritis (axSpA) is increasing. Thus, it has become more challenging for patients and physicians to navigate the risk‐benefit profiles of the various treatment options. In this study, we used conjoint analysis—a form of trade‐off analysis that…

  16. Artikel Jurnal

    Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2

    Sofia Ramiro; Atul Deodhar; Philip J Mease dkk.

    RMD Open, Vol. 10 No. 2 · 2024 · Inggris · DOAJ Scopus

    Objective To assess how achievement of increasingly stringent clinical response criteria and disease activity states at week 52 translate into changes in core domains in patients with non-radiographic (nr-) and radiographic (r-) axial spondyloarthritis (axSpA).Methods Patients in BE MOBILE 1 and 2…

  17. Artikel Jurnal

    Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies

    Atul Deodhar; Philip J Mease; Martin Rudwaleit dkk.

    RMD Open, Vol. 11 No. 4 · 2025 · Inggris · DOAJ Scopus

    Objective To assess the long-term effect of bimekizumab, a dual inhibitor of IL-17A and IL-17F, on patient-reported symptoms, function and health-related quality of life (HRQoL) in patients with axial spondyloarthritis (axSpA) from phase 3 studies and their open-label extension.Methods BE MOBILE 1…

  18. Artikel Jurnal

    Guselkumab versus golimumab in patients with active psoriatic arthritis and inadequate response to an initial tumor necrosis factor inhibitor: study protocol for EVOLUTION, a pragmatic, phase 3b, open-label, randomized, controlled effectiveness trial

    Alexis Ogdie; Soumya M. Reddy; Sarah H. Gillespie dkk.

    Trials, Vol. 26 No. 1 · 2025 · Inggris · DOAJ Scopus

    Abstract Background Psoriatic arthritis (PsA) is a multi-domain, inflammatory disease impacting joints, soft tissues, and skin; tumor necrosis factor inhibitors (TNFi) are typically the first biologic following inadequate response (IR) to conventional therapies. Although guidance is lacking on…